Patient and physician preferences for oral pharmacotherapy for overactive bladder: two discrete choice experiments

References

• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37-49
   PubMed Web of Science ®Google Scholar
• Homma Y, Yamaguchi O, Hayashi K. An epidemiological survey of overactive bladder symptoms in Japan. BJU Int 2005;96:1314-18
   PubMed Web of Science ®Google Scholar
• Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-6
   PubMed Web of Science ®Google Scholar
• Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36
   PubMed Web of Science ®Google Scholar
• Nitti VW, Khullar V, van Kerrebroeck P, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract 2013;67:619-32
   PubMed Web of Science ®Google Scholar
• Watson V, Ryan M, Brown CT, et al. Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2004;172(6 Pt 1):2321-5
   PubMed Web of Science ®Google Scholar
• Swinburn P, Lloyd A, Ali S, et al. Preferences for antimuscarinic therapy for overactive bladder. BJU Int 2011;108:868-73
   PubMed Web of Science ®Google Scholar
• Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ 2000;320:1530-3
   PubMed Web of Science ®Google Scholar
• World Medical Association. Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects (2013 Revision). Fortaleza, Brazil: World Medical Association, Inc., 2013
   Google Scholar
• Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002;11:563-74
   PubMed Web of Science ®Google Scholar
• Young T, Yang Y, Brazier JE, et al. The first stage of developing preference-based measures: constructing a health-state classification using Rasch analysis. Qual Life Res 2009;18:253-65
   PubMed Web of Science ®Google Scholar
• Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006;49:1079-86
   PubMed Web of Science ®Google Scholar
• Cartwright R, Panayi D, Cardozo L, Khullar V. Reliability and normal ranges for the Patient’s Perception of Intensity of Urgency Scale in asymptomatic women. BJU Int 2010;105:832-6
   PubMed Web of Science ®Google Scholar
• Rabin R, De Charro F. EQ-SD: a measure of health status from the EuroQol Group. Ann Med 2001;33:337-43
   PubMed Web of Science ®Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353-65
   PubMed Web of Science ®Google Scholar
• Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004;93:303-10
   PubMed Web of Science ®Google Scholar
• Harpe SE, Szeinbach SL, Caswell RJ, et al. The relative importance of health related quality of life and prescription insurance coverage in the decision to pharmacologically manage symptoms of overactive bladder. J Urol 2007;178:2532-6
   PubMed Web of Science ®Google Scholar
• Michel MC, Oelke M, Goepel M, et al. Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients. Neurourol Urodyn 2007;26:190-5
   PubMed Web of Science ®Google Scholar
• Astellas. Summary of Product Characteristics, Vesicare 5mg & 10mg (Dutch). Leiden, The Netherlands: Astellas Pharma Europe B.V., 2013
   Google Scholar
• Astellas. Summary of Product Characteristics, Betmiga 25mg & 50mg (Dutch). Leiden, The Netherlands: Astellas Pharma Europe B.V., 2014
   Google Scholar
• Astellas Pharma Europe B.V. ISN/Protocol 178-CL-102, Master Informed Consent Form. London, United Kingdom: EU Clinical Trials Register, European Medicines Agency, 2012
   Google Scholar
• Reed Johnson F, Lancsar E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health 2013;16:3-13
   PubMed Web of Science ®Google Scholar
• Bridges JFP, Hauber AB, Marshall D, et al. Conjoint analysis applications in health – a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health 2011;14:403-13
   PubMed Web of Science ®Google Scholar
• Baron J. Confusion of relative and absolute risk in valuation. J Risk Uncertain 1997;14:301-9
   Web of Science ®Google Scholar
• Featherstonhaugh D, Slovic P, Johnson S, Friedrich J. Insensitivity to the value of human life: a study of psychological numbing. J Risk Uncertain 1997;14:283-300
   Web of Science ®Google Scholar
• Gormley EA, Lightner DJ, Burgio KL, et al. American Urological Association (AUA) Guideline. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults. AUA/SUFU Guideline. Linthicum, MD, USA: American Urological Association, 2014
   Google Scholar
• Wu JM, Fulton RG, Amundsen CL, et al. Patient preferences for different severities of and treatments for overactive bladder. Female Pelvic Med Reconstr Surg 2011;17:184-9
   PubMed Web of Science ®Google Scholar
• Agarwal A, Eryuzlu LN, Cartwright R, et al. What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women. Eur Urol 2015;65:1211-17
   Web of Science ®Google Scholar
• Department of Health and Human Services Food and Drug Administration. Patient Preference Information – Submission, Review in PMAs, HDE Applications, and De Novo Requests, and Inclusion in Device Labeling. Fed Regist Vol 80, No 95. Available at: http://www.noticeandcomment.com/FDA-2015-D-1580-fdt-76214.aspx [issued on May 18, 2015]
   Google Scholar